Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Hydrogen Bromide | HCID 260 | — |
| Reactant | HCID 131730406 | HCID 131730406 | — |
| Product | HCID 66732220 | HCID 66732220 | 86% |
Reaction Steps
Trans-methyl 2-(2-chloro-4-fluorophenyl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-1-carboxylate (130 mg, 0.37 mmol) (from example 47, step 3) was dissolved in hydrogen bromide (33% in acetic acid, 2.9 mL, 16.49 mmol) and stirred at room temperature for 16 h. The solvent was removed and the residue purified by preparative HPLC (Instrument: FractionLynx II, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm) to yield 5-(Trans-2-(2-chloro-4-fluorophenyl)piperidin-4-yl)isoxazol-3(2H)-one (94 mg, 86%). 1H NMR (600 MHz, dmso) δ 1.50-1.60 (m, 1H), 1.79-1.88 (m, 1H), 1.95-2.01 (m, 1H), 2.06-2.12 (m, 1H), 2.70 (t, 1H), 2.88-2.96 (m, 1H), 3.20-3.24 (m, 1H), 4.01 (d, 1H), 5.95 (d, 1H), 7.21 (dt, 1H), 7.37 (dd, 1H), 7.68 (dd, 1H). HRMS Calculated for [C14H14ClFN2O2+H]+: 297.0806. Found: 297.0823
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08415378B2 |
|---|
| Source dataset | uspto-grants-2013_04 |
|---|
| ORD ID | ord-b12a0d9524f547339fe630e02c12e6a3 |
|---|
| Source note | uspto-grants-2013_04 |
|---|